Sobi Ramps Up In Rare Diseases With Apellis Deal
$250m Upfront Fee For Rights To Pegcetacoplan
Executive Summary
Sobi is paying big bucks to tap into the potential of Apellis's pegcetacoplan, a targeted C3 therapy for the treatment of multiple rare diseases with high unmet need which the partners say impact more than 275,000 patients globally.
You may also be interested in...
Japan Sets Luxturna, Other New Prices While Cutting Selected Fast Growers
Six new drugs including Luxturna will be price-listed in Japan on 30 August, with the Novartis gene therapy set to become the second-most expensive therapeutic product in the country. Behind another round of market expansion-related price cuts for selected drugs, discussions on possible changes to the repricing system are ongoing.
Sobi Returns To Deal-Making With ADC Lymphoma Licensing Pact
The Swedish rare disease specialist has expanded its hematology franchise by getting the European rights to ADC Therapeutics’ Zynlonta, which has yet to make much impact commercially in the US.
Apellis Says Mixed Phase III Results Position Geographic Atrophy Candidate For Filing
Apellis plans to file pegcetacoplan for approval as the first drug to treat the advanced AMD condition geographic atrophy, despite the C3 inhibitor hitting its endpoint in only one of two pivotal trials.